Bristol-Myers Squibb is putting down a hefty sum to buy a company developing a drug for a rare cardiovascular disease. The New York-based drugmaker said Monday that it would spend $13.1 billion to ...

In trading on Tuesday, shares of Bemis Co Inc (NYSE: BMS) crossed above their 200 day moving average of $38.99, changing hands as high as $39.00 per share. Bemis Co Inc shares are currently trading ...

A partnership between two drugmakers and a company that makes fitness trackers aims to address gaps in the diagnosis of atrial fibrillation. New York-based drugmakers Bristol-Myers Squibb and Pfizer – ...

Bristol-Myers Squibb (BMS) and Enterome said today they will partner to discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules as potential treatments and companion ...

Why is Jim Cornelius (photo) smiling? His big promotion to permanent CEO of Bristol-Myers Squibb last year came with a mighty boost in pay. According to the Wall Street Journal's calculations, ...

In proximal lesions of the left anterior descending (LAD) artery, percutaneous coronary intervention (PCI) with bare-metal stents (BMS) yields equivalent outcomes compared with minimally invasive ...

Bristol-Myers Squibb (BMS) has signed a long-term agreement with Samsung BioLogics that will see the Korean firm manufacture one of its antibody cancer drugs. Technology transfer and trial production ...

Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses is one path to excess returns. For example, long term Braemar Plc (LON:BMS) ...